🇺🇸 FDA
Patent

US 12116573

Targeting ligands for therapeutic compounds

granted A61KA61K31/713A61K47/549

Quick answer

US patent 12116573 (Targeting ligands for therapeutic compounds) held by Arrowhead Pharmaceuticals, Inc. expires Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Oct 15 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 10 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K31/713, A61K47/549, A61P, A61P43/00